Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study

References

• Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894–1907. doi:10.1016/S0140-6736(06)69780-8
   PubMed Web of Science ®Google Scholar
• Nagel G, Weber D, Fromm E, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96(12):1993–2003. doi:10.1007/s00277-017-3150-3
   PubMed Web of Science ®Google Scholar
• Hilberink J, Hazenberg C, van den Berg E, et al. Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: a single center experience of 355 consecutive patients. Leuk Res. 2019;80:33–39. doi:10.1016/j.leukres.2019.03.004
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116(13):2224–2228. doi:10.1182/blood-2010-02-270330
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Vachhani P, Al Yacoub R, Miller A, et al. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: a single center experience. Leuk Res. 2018;75:29–35. doi:10.1016/j.leukres.2018.10.011
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a Phase III randomized study of the Leukemia Cooperative Group of European Organisation for the research and treatment of cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90(8):2952–2961.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235–1248. doi:10.1056/NEJMoa0901409
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Sharplin K, Wee LYA, Singhal D, et al. Outcomes and health care utilization of older patients with acute myeloid leukemia. J Geriatr Oncol. 2021;12(2):243–249. doi:10.1016/j.jgo.2020.07.002
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–3485. doi:10.1182/blood-2005-09-3724
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storer BE, Fathi AT, et al. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood. 2021;138(5):387–400. doi:10.1182/blood.2020008812
   PubMed Web of Science ®Google Scholar
• Récher C, Röllig C, Bérard E, et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia. 2021. PMID: 34775483. doi:10.1038/s41375-021-01425-9
   Web of Science ®Google Scholar
• Østgård LS, Nørgaard JM, Sengeløv H, et al. Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. Leukemia. 2015;29(3):548–555. doi:10.1038/leu.2014.234
   PubMed Web of Science ®Google Scholar
• Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):357–363. doi:10.1370/afm.983
   PubMed Web of Science ®Google Scholar
• Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889–3897. doi:10.1200/JCO.2012.45.9628
   PubMed Web of Science ®Google Scholar
• Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34(4):329–336. doi:10.1200/JCO.2015.63.3826
   PubMed Web of Science ®Google Scholar
• Hilberink JR, Morsink LM, van der Velden WJFM, et al. Pretransplantation MRD in older patients with AML after treatment with decitabine or conventional chemotherapy. Transplant Cell Ther. 2021;27(3):246–252. doi:10.1016/j.jtct.2020.12.014
   PubMedGoogle Scholar
• Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31(32):4123–4131. doi:10.1200/JCO.2013.49.1753
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117(8):2366–2372. doi:10.1182/blood-2010-07-295279
   PubMed Web of Science ®Google Scholar
• Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–2361. doi:10.1001/jama.2009.813
   PubMed Web of Science ®Google Scholar
• Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98(3):548–553. doi:10.1182/blood.v98.3.548
   PubMed Web of Science ®Google Scholar
• Sperr WR, Piribauer M, Wimazal F, et al. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Clin Cancer Res. 2004;10(12 Pt 1):3965–3971. doi:10.1158/1078-0432.CCR-04-0185
   PubMed Web of Science ®Google Scholar